mw medical - keine Umsätze mehr?????? - 500 Beiträge pro Seite

[ROBAU]

seit einigen Tagen kann ich keine Umsätze, nach Kursverlusten (-80%)in USA feststellen.
Weiß jemand was neues???

[Sweet666]

Hallo Robau,
habe im Consors-Board gehört, dass mw medical in den usa auf den pink-sheets ist und dass sie ein neues Kürzel haben. Im grossen und ganzen sieht es wohl nicht sehr gut aus. Ich kenne mich da nicht so aus, ich bin erst Anfänger und mit mw medical höchstwahrscheinlich tierisch in die Falle getappt. Die Leute im Consors-Board meinten, dass mw medical demnächst Pleite ist!???? Was soll´s?? Grüsse Sweet

[ROBAU]

Hallo sweet 666,

vielen Dank für deine leider nicht so gute Nachricht.
Meine neuesten Infos:

CEO ausgewechselt!!1
aktuell wieder Umsätze ca St. 30.000 in den letzen 3 Tagen.
das Kürzel ist weiter mwmd.ob
bis dann

[Sweet666]

Hallo Robau,
danke für Deine Infos. Kannst Du mir das bitte auch übersetzen??
Ich bin noch nicht so lange dabei und mir sagt CEO leider nichts. Ist das jetzt eine gute Neuigkeit oder nicht? Vielen Dank.
Gruß
Sweet

[ROBAU]

hallo sweet,

ceo heißt chief executive officer oder auf Deutsch Geschäftsführer oder Vorstand.

Ich denke das sind keine so guten Nachrichten aber so tief wie der Kurs in den letzten Wochen gefallen kann er nicht mehr fallen. Also ich habe die gleiche Summe die ich im April investiert habe noch einmal reingesteckt und warte jetzt ab.
bis dann
ROBAU

[BBBio]

Ich habe die Dinger leider auch noch, haben sich leider gerade gefünftelt. Könnte nach dem, was man so hört, nicht sagen, dass ich zuversichtlich bin, aber verkaufen lohnt jetzt auch nicht mehr.

Bin normalerweise ja kein Fundi, aber bei diesem Wert würde mich trotzdem interessieren, was fundamental dahintersteckt?

[ROBAU]

mw medical haben ein System entwickelt, dass angeblich besser und billiger als die herkömliche Lasertechnologie für Schönheitsoperationen verwandt wird. Diese Technologie ist auf Microwellenbasis konzipiert. Die Vermarktung erfolgt ebenfalls über mwmd.
Die ersten Geräte sind an Ärzte ausgeliefert.

In Deutschland ist der Wert über Raymond James Meerbusch promotet worden. Im April gab es in Deutschland eine Road Show. Allerdings schwankte der Kurs um 3-4 USD.

Aus welchem Grund es zu der Schwäche und Auswechlung der Führung kam kann ich allerdings nicht sagen.
Bis dann

[Moneteus]

Hallo Leute,
wen es interessiert warum genau sein Geld in den letzten Wochen bei MW Medical vernichtet wurde, der kann sich ja mal gerne den Jahresbericht und auch den letzten Quartalsbericht durchlesen(auffindbar unter Yahoo Finance!).
Macht alles in allem nicht gerade den besten Eindruck, aber verkaufen lohnt sich halt nicht mehr. Bleibt nur zu hoffen, dass es nochmal aufwärts geht in den nächsten Monaten (kurzfristige Kurszielemachen jetzt wohl keinen Sinn mehr).
Tschö,Moneteus.



May 09, 2000
MW MEDICAL INC (MWMD.OB)
Annual Report (SEC form 10KSB)
Management`s Discussion and Analysis or Plan of Operation
Please note that the Company`s audited Financial Statements have not been included at this time as they were not completed in time for this filing. The Company anticipates filing an amended form 10KSB before the end of April with said financials included. As a result, management cannot comment effectively on the results of operation or on the Company`s financial condition in this section at this time.
Over the past several months the Company has been faced with a number of problems in bringing its new product to market. In addition, to the more traditional difficulties of generating sales, its vice president of marketing and national sales manager resigned in January and it discovered that a number of the sales it thought had been made had not actually occurred. Following this, the company has been actively involved in hiring and training new sales executives and personnel, but the process has been slow and costly.
Management believes that these difficulties will be overcome and that the company will recover with new marketing and support personnel by the end of the second quarter.
Default on Note Payment by Purchaser of P&H
The Company sold the business of P&H Laboratories, Inc. ("P&H") to Microwave Communication Corporation ("MCC") on March 9, 1998. Pursuant to the agreement of sale, MCC signed a promissory note payable to P&H in which it was obligated to pay
$250,000 to P&H on August 1, 1998 and $243,125 on March 31, 1999. P&H later assigned its rights under this note to the Company.
The payment due on March 31, 1999 has not been received. The Company re-negotiated a new payment schedule, but MCC defaulted on this obligation in July. The company has submitted documentation to the defaulting parties to restructure repayment of their obligations. The company intends to proceed with enforcement of its claims unless this documentation is executed and timely returned.
Prior Period Adjustments
In 1998, the Company`s former parent, Dynamic Associates, Inc., as part of its spin-off of MW, agreed to cancel MMC`s debt of $2,169,806. MW recognized this discharge of indebtedness as earnings for the year ended December 31, 1998. After careful review, the Company changed this entry on its books to a capital transaction, and thus decrease net income by $2,169,806 and increased additional paid in capital by a like amount.
Additionally, as part of the spin off, Dynamic agreed to pay the Company $200,000 to help in its start-up. MW originally entered this item as a receivable on its books. In 1999, Dynamic paid MW, $50,000 towards this debt. After careful review, the Company changed this entry to a capital transaction, thereby decreasing net income by $200,000 and reclassifying the receivable into stockholders` equity.
General Discussion
Despite initial efforts, the Company`s sales efforts have not met management`s expectations. Management now believes that there will be a period of at least six months before it will be able to generate enough sales to offset operating and other expenses. Moreover, the Company continues to deal with a number of issues regarding the use and operation of the MW 2000 by physicians and their staff which suggests that there will be at least this same amount of time before initial operational problems will be resolved. In the meantime, management expects the return of a number of machines and continual internal evaluation of such things as warning labels and operating instructions.
Impact of the Year 2000 Issue
The "Year 2000 problem" arose because many existing computer programs use only the last two digits to refer to a year. Therefore, these computer programs do not properly recognize a year that begins with "20" instead of the familiar "19". The Company has not experience any difficulties as a result of this potential problems.
Item 7. Financial Statements
The information required by this item is set forth in Item 13 of this Report.
Item 8. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
We have had no changes in or disagreements with our accountants on accounting or financial disclosures.








May 19, 2000
MW MEDICAL INC (MWMD.OB)
Quarterly Report (SEC form 10QSB)
Management`s Discussion and Analysis of Financial Condition and Results of Operations.
Through the first quarter 2000, the Company has concentrated on re-structuring its management and organization, and has been working to solve problems with its MW 2000 machine, its product sales and its training and supportive clinical documentation programs.
The Company has a new national sales manager, an in-house sales person and a seasoned distributor. The Company is also in the process of adding replacement and additional support personnel, including a new C.E.O., C.F.O., marketing director, product and quality assurance manager, three clinical nurses and an inventory/shipping manager. Management hopes to have the new people in these positions by the beginning of the third quarter, but will need to secure financing before this task can be completed. At that time, the Company also plans to re-launch its product into the market.
The Company has also expanded its clinical sites. It is hoped that this expansion will provide the Company with a number of peer review publications and clinical white papers from medical luminaries in the field of dermatology, pheblology, plastic surgery and other specialties. It may also provide individuals who can be called upon to lecture on the merits of MW`s microwave technology. Management expects to have one such article written by Dr. Nicholas Lowe available in the coming weeks.
Management believes that it will require additional funds to continue operations in the second or third quarter of this year. The Company completed a private placement of 1,000,000 shares of the Company`s common stock in January 2000. Net cash proceeds from this placement were $2,400,000. The Company intends to complete another equity offering to fund operations until sufficient funds are derived from sales revenues. For this purpose, the Company will also be looking for a strategic partner or strong national sales distribution organization to expand its sales opportunities. The Company has been able to raise funds through equity and debt offerings in the past; however, the Company can offer no guarantee that it will be able to raise sufficient funds in the future or that cash flows from revenues will ever be achieved. Failure to obtain additional financing or generate cash flows from revenues would have a material adverse effect on the Company.
Assets
Total assets of the Company increased to $5,362,071 on March 31, 2000 from $4,117,108 on December 31, 1999, an increase of $1,244,963 or 30%. The net change resulted primarily from an increase in cash and inventory. The Company`s increase of its cash resulted primarily from its sale of $3,000,000 in common stock in January 2000. The increase in inventory of approximately $431,000 is the result of the Company`s initial production of its MW 2000 systems in anticipation of the product re-launch later this year.
Liabilities And Stockholders` Equity
The Company`s asset growth for the three months ending March 31, 2000 was funded by increased stockholders` equity and short-term borrowings. Stockholders` equity increased $1,090,627, or 47%, to $3,415,191 as of March 31, 2000. The net increase in stockholders`
equity resulted primarily from the sale of common stock, approximately $2,400,000, net, and the exercise of stock options, less the net loss from operations.
Short-term borrowings were made from the Company`s line of credit.
Results of Operations
The Company began its initial production of the MW 2000 machines and delivered 36 of the machines to clinical sites across the country. Of these 36 machines, the Company has taken back four machines, 10 are with its national distributor pending order placement, 10 are involved in clinical trials and 12 have been returned to the Company`s inventory to receive upgrades or other product modification.
Net loss for the three months ended March 31, 2000 was $1,367,372 compared to a loss of $389,566 during the same period in 1999. This increase in the net loss was caused by the Company ramping up production and establishing the necessary internal infrastructure to accommodate the projected growth expected in connection with the re-launch of the MW 2000 machine.
General and administrative expenses for the three months ended March 31, 2000 were $1,124,905 compared to $254,535 for the same period in 1999. This reflects an increase of $870,370, or 342%. This increase was primarily due to advertising and promotion cost involved in bringing the product to market and an increase in professional fees.
Research and development expenses were $242,946 for the three months ended March 31, 2000 compared to $117,515 for the same period in 1999. The increase of $125,431 reflects the Company`s continued research into additional applications for its microwave technology.
Depreciation and amortization expenses for the three months ended March 31, 2000 were $4,945 compared to $24,672 for the same period in 1999. The decrease in depreciation was due to a decrease in the amount of depreciable assets. Depreciable assets as of December 31, 1999 and for the majority of the first quarter of 2000 totaled approximately $21,100.
Despite initial efforts, the Company`s sales have not met management`s expectations. Management believes the Company will begin generating revenues late in the second or during the third quarter of 2000 with significant revenues being generated in the fourth quarter. The Company has and continues to deal with a number of issues and problems regarding the use and operation of the MW 2000 machine by physicians and their staff. In response to these issues, management has implemented a continuing internal evaluation process that has resulted in planned modifications and upgrades to the MW 2000 machine, including such things as warning labels, instruction manuals, on-site training, and clinical support. Management believes that the MW 2000 machine will be ready for its re-launch in the late second or early third quarter of 2000.
Liquidity and Capital Resources
As of March 31, 2000, the Company had $1,147,311 in cash. During the first quarter of 2000, The Company completed a private placement of 1,000,000 shares of the Company`s common stock. Net cash proceeds from this placement were $2,400,000.
The Company used cash of $1,650,409 in its operating activities during the three months ending March 31, 2000 compared to $255,126 for the same period in 1999. In the first quarter of 2000, the Company was primarily involved in product upgrades, re-structuring management and in enhancing internal procedures. The Company has only begun the production of the MW 2000 in the fourth quarter of 1999 and will require substantial additional financing in the future to continue the operations. Management intends to obtain financing through additional equity offerings until such time as cash flows from operations are sufficient to support the Company. Management believes that it will be able to raise the money that is necessary, but currently does not have this financing in place.
Forward-Looking Statements
Many statements made in this report are forward-looking statements that are not based on historical facts. Because these forward- looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward- looking statements. The forward-looking statements made in this report relate only to events as of the date on which the statements are made.
Item 3.
None
Item 4.
None

[ROBAU]

mw Medical hat eine neue Manschaft
hier die news:

MW Medical Expands Management Team
SCOTTSDALE, Ariz., June 23 /PRNewswire/ -- MW Medical, Inc. (OTC Bulletin Board: MWMD - news) today announced the appointment of several key employees to the company`s operation.

Herb Rippley has joined the company as National Sales Manager; Tom Paulino, as Senior Manager, Technical Services and Support; and Judy Vandelac, joins as Clinical Manager.

Mr. Rippley brings over sixteen years of medical sales and sales management experience to the company. In previous appointments, with companies such as ESC Medical Systems, Sunrise Technologies and Mentor O&O, Rippley managed sales organizations with national coverage responsibilities. At these companies, Mr. Rippley was rewarded and promoted for sales and leadership achievements numerous times. As a sales manager, Rippley has been particularly successful expanding the use of medical technologies to new markets and applications.

``I`m very excited to be joining MW at this time. The company has an excellent technology foundation, the product is technically and functionally solid and the demand for its current capability and future applications is strong. With the data we`re seeing from the clinical sites, this first product is proving it will be the core of a revolutionary product family,`` stated Rippley.

Mr. Rippley also brings to MW his outstanding contacts in both the medical community and distributor networks. Rippley`s immediate focus includes establishing MW`s North American sales function, and implementing the sales systems and controls the company needs as it re-launches it`s microwave hair removal system, the MW 2000. ``Herb`s experience and credibility with the field sales team and customers, particularly in the aesthetic marketplace, will be invaluable for MW Medical as we rebuild our distribution system,`` stated Jan Wallace, Chairman and CEO of MW Medical.

Mr. Paulino, brings fifteen years of medical device experience in service, technical support, clinical support, product development and marketing experience to MW Medical. With previous companies, Mr. Paulino specialized in the development and introduction of new devices. His past experience with one of the earliest Ruby hair removal lasers will be invaluable in supporting the MW 2000 hair removal product. Most recently, Paulino worked on the development and introduction of cosmetic and surgical laser products for a leading supplier. Mr. Paulino`s experiences, in development, support and especially his relationships in the industry bring depth to MW Medical.

``I`m extremely motivated and challenged about being a part of this company and very pleased with the MW 2000`s versatility. The system is capable of results other modalities cannot deliver,`` said Paulino. ``The MW 2000`s core platform is very durable and scaleable in its ability to deliver RF energy to meet the changing needs and demands in existing and evolving medical applications. Hair Removal is just the beginning of what microwave energy can be used for medically.``

In addition to his technical skills, Mr. Paulino comes to MW Medical with the experience of working closely with influential physicians in the cosmetic and surgical fields. He was recently, Program Manager for a leading manufacturer of surgical and aesthetic lasers and intense pulsed light systems. While there, Paulino held numerous positions in the service and technical departments, and most recently in marketing. In 1996 he was the Product Manager of the Ruby and Alexandrite Hair Removal Lasers. In this role, Paulino was integrally involved in all aspects of these products` clinical and technical development.

Judy Vandelac joins MW Medical as Clinical Manager and will manage the company`s clinical study and research activities. Additionally, Ms. Vandelac will be implementing clinical training programs in the use and safety of the MW devices. Ms. Vandelac is a Registered Nurse with over ten years experience in the laser industry. She is a Certified Laser Technician, and has worked in research and development for several aesthetic and surgical device companies.

Ms. Vandelac trained physicians and medical staff members on device operation and safety in the U.S. and internationally since 1994. Her skills and experience in this area enable her to lead MW`s clinical education efforts in hair removal, vein reduction and other applications the company is commercializing with the new MW 2000 system. Vandelac`s proficiency and experience with all lasers used in the aesthetic market over the last decade provides MW Medical with a unique perspective on the clinical performance of its products. She has supported and trained operators on the use of lasers such as CO2, Erbium, Nd:Yag, Ruby, Alexandrite, and several Pulsed Light systems.

``A key benefit to Judy joining MW is her wealth of knowledge, both from a medical perspective as well as tissue interaction using laser, pulsed light and now microwave energy,`` stated Jan Wallace. Vandelac is leading several FDA sanctioned clinical trials now in progress and is responsible for educating and training physicians in the proper use of the MW 2000.

The addition of these key individuals, all with significant medical and particularly aesthetic industry experience, gives MW Medical substantial credibility in the industry. ``Our ability to demonstrate clinical efficacy and substantial growth potential enabled us to attract people of this group`s experience, stature and reputation in the industry. It definitely helps establish the company and the MW 2000 in the industry. This group rounds out MW`s sales, technical support and clinical management team. With these additions, MW can now confidently position itself and its products in the market``, stated Wallace.

Statement Under the Private Securities litigation Reform Act With the exception of the historical information contained in this release, the matters described herein contains forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product acceptance, economic, competitive, governmental, results of litigation, technological and/or other factors, which are outside the control of the Company.

SOURCE: MW Medical, Inc.

[BBBio]

Jetzt massive Umsätze und Kurssteigerungen! 0,843 Dollar